Boehringer assures future growth following sales drop
pharmafile | April 23, 2015 | News story | Sales and Marketing | Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results
Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and flat earnings.
Its latest annual financial statement reports that net income dropped 21% to €1.05 billion ($1.13 billion) last year from €1.32 billion in fiscal 2013. Global sales declined 5.3% to €13.3 billion. Full-year operating profit came in at €2.1 billion the German family-owned group notes.
Remaining upbeat however is its board chairman Professor Andreas Barner, who says: “After a challenging 2014, the focus for us now is on launching numerous additional new products and on our profitability.
“We were able to submit a large number of compounds for marketing authorisation in 2014 and, with research and development expenditure amounting to just close to €2.7 billion, we have invested once again in the future.”
Boehringer now expects for the current financial year a moderate increase in net sales compared with the last, and is keen to point out that it employed more than 47,700 people worldwide in 2014, which is around 1% more than in 2013.
It will now be pinging its hopes on new medicines submitted for marketing authorisation, namely Striverdi Respimat (olodaterol) for COPD patients, Jardiance (empagliflozin) and Glyxambi (empagliflozin/linagliptin), for the treatment of type 2 diabetes.
Then there’s the promising Ofev (nintedanib) for the treatment of idiopathic pulmonary fibrosis and, at the beginning of January 2015 with the same compound, comes Vargatef for advanced lung cancer patients with adenocarcinoma following chemotherapy.
Boehringer will no doubt be pleased to be making strides in the digital realm too for signalling a brighter future, which just arrived in the shape of being named as a social media leader via an industry study.
Barner adds: “In our view, Boehringer Ingelheim is well-positioned for future growth. Despite the difficult market environment, we are therefore planning in 2015 for a moderate increase in net sales compared with the previous year.”
Brett Wells
Related Content
Verona Pharma to share phase 3 COPD trial data at ATS 2024
Verona Pharma has announced that it will share eight posters at the American Thoracic Society …
Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment
Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …
Verona Pharma submits FDA New Drug Application for COPD treatment
UK-based Verona Pharma has announced that it has submitted a New Drug Application (NDA) to …
